



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	WYTH-P01-002
-------	---	----	---	------------------------	--------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
GE	AA	US-5,864,018	01-26-1999	Schering Aktiengesellschaft	
	AB	US-5,891,341	04-06-1999	The Picower Institute for Medical Research	
	AC	US-6,007,865	12-28-1999	Alteon Inc.; The Picower Institute for Medical Research	
	AD	US-6,380,165-B1	04-30-2002	The Picower Institute for Medical Research	
	AE	US-6,440,749-B1	08-27-2002	Alteon, Inc.; The Picower Institute for Medical Research	
	AF	US-5,656,261	08-12-1997	The Picower Institute for Medical Research; Alteon Inc.	
	AG	US-5,853,703	12-29-1998	The Picower Institute for Medical Research; Alteon Inc.	
	AH	US-2001/0039256-A1	11-08-2001	Stern, et al.	
	AI	US-2001/0053357-A1	12-20-2001	Stern, et al.	
	AJ	US-2002/0002203-A1	01-03-2002	Rahbar	
	AK	US-2002/0013256-A1	01-31-2002	Rahbar, et al.	
	AL	US-2002/0022234-A1	02-21-2002	Al-Abed, et al.	
	AM	US-2002/0037496	03-28-2002	Jacobson, et al.	
	AN	US-2002/0077293-A1	06-20-2002	Cahoon, et al.	
	AO	US-2002/0082273-A1	06-27-2002	Bush, et al.	
	AP	US-2002/0086282-A1	07-04-2002	Pillarisetti, et al.	
	AQ	US-2002/0106726-A1	08-08-2002	Schmidt, et al.	
↓	AR	US-2002/0116725-A1	08-22-2002	Stern, et al.	
	AS	US-2002/0122799-A1	09-05-2002	Stern, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
GE	BA	WO-00/18970-A1	04-06-2000	Asahi Kasei Kogyo Kabushiki Kaisha		
	BB	WO-00/20458-A1	04-13-2000	The Trustees of Columbia University in the City of New York		
	BC	WO-00/20621-A1	04-13-2000	The Trustees of Columbia University in The City of New York		
	BD	WO-01/05422-A1	01-25-2001	BioMerieux Stelhys		
	BE	WO-01/12598	02-22-2001	The Trustees of Columbia University in The City of New York		
	BF	WO-01/18060-A1	03-15-2001	Toray Industries, Inc.		
↓	BG	WO-01/029269	04-26-2001	Case Western Reserve University		
	BH	WO-01/76584	10-18-2001	City of Hope		

Examiner Signature	/Gregory Emch/	Date Considered	09/14/2006
--------------------	----------------	-----------------	------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/643589
				Filing Date	August 18, 2003
				First Named Inventor	Debra D. Pittman
				Art Unit	1649
				Examiner Name	Not Yet Assigned G. S. Emch
Sheet	2	of	3	Attorney Docket Number	WYTH-P01-002

GE	BI	WO-01/079849	10-25-2001	Trans Tech Pharma	
	BJ	WO-01/086002	11-15-2001	Genetics Institute, LLC; The Rockefeller University	
	BK	WO-01/92210-A1	12-06-2001	Trans Tech Pharma	
	BL	WO-01/092892	12-06-2001	Transtech Pharma, Inc.	
	BM	WO-02/30889	04-18-2002	The Trustees of Columbia University in The City of New York	
	BN	WO-02/030889	04-18-2002	The Trustees of Columbia University in The City of New York	
	BO	WO-02/066978	08-29-2002	Reddy US Therapeutics, Inc.	
	BP	WO-02/068636-A1	09-06-2002	Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V.	
	BQ	WO-02/14519-A1	02-21-2002	The Trustees of Columbia University in The City of New York	
	BR	WO-97/26913-A1	07-31-1997	The Trustees of Columbia University in The City of New York	
	BS	WO-97/39125-A1	10-23-1997	Schering Aktiengesellschaft Patente	
	BT	WO-98/22138-A1	05-28-1998	The Trustees of Columbia University in The City of New York	
	BU	WO-98/40071-A1	09-17-1998	The General Hospital Corporation	
	BV	WO-99/07402-A1	02-18-1999	The Trustees of Columbia University of The City of New York	
	BW	WO-99/18987-A1	04-22-1999	The Trustees of Columbia University of The City of New York	
	BX	WO-99/45907-A2	09-16-1999	The General Hospital Corporation	
▼	BY	WO-99/54485-A1	10-28-1999	The Trustees of Columbia University in The City of New York	
	BZ	WO-97/39121-A1	10-23-1997	Schering Aktiengesellschaft	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
Examiner Signature	/Gregory Emch/			Date Considered	09/14/2006



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/643589
				Filing Date	August 18, 2003
				First Named Inventor	Debra D. Pittman
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	WYTH-P01-002

GE	CA	Schmidt, et al., "The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses," J. Clin. Invest. 949-955, Vol. 108(7), October 2001.	
----	----	---	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Gregory Emch/	Date Considered	09/14/2006
--------------------	----------------	-----------------	------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/643589
				Filing Date	August 18, 2003
				First Named Inventor	Debra D. Pittman
				Art Unit	1646 1649
				Examiner Name	Not Yet Assigned G. S. Emch
Sheet	1	of	1	Attorney Docket Number	WYTH-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
GE	AT	2002/0006391 A1	1/17/02	Smith et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		
					T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
GE	CB	Du Yan, S. et al., "Amyloid- β peptide-Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A Proinflammatory pathway in Alzheimer disease", Proc. Natl. Acad. Sci., 94:pp. 5296-5301 (1997)			
	CC	Hori, et al., "The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphotericin", The Journal of Biological Chemistry, 270(43), pp. 25752-25761 (1995)			
	CD	Li, J., et al., "Sp1-binding Elements in the Promoter of RAGE Are Essential for Amphotericin-mediated Gene Expression in Cultured Neuroblastoma Cells", The Journal of Biological Chemistry, 273(47), pp. 30870-30878 (1998)			
	CE	Schmidt, A. et al., "Receptor for Advanced Glycation End Products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins", Proc. Natl. Acad. Sci., 91:pp. 8807-8811 (1994)			
	CF	Tanaka, et al., "The Receptor For Advanced Glycation End Products is Induced by the Glycation Products Themselves and Tumor Necrosis Factor- α through Nuclear Factor-kB, and by 17 β -Estradiol through Sp-1 in Human Vascular Endothelial Cells", The Journal of Biological Chemistry, 275(33), pp. 25781-25790 (2000)			
▼	CG	Wautier, et al., "Receptor-mediated Endothelial Cell Dysfunction in Diabetic Vasculopathy. Soluble Receptor for Advanced Glycation End Products Blocks Hyperpermeability in Diabetic Rats", J. Clin. Invest., 97(1) pp. 238-243 (1996)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Gregory Emch/	Date Considered	09/14/2006
--------------------	----------------	-----------------	------------